Biologics, DNA Plasmid Vaccine
Total Trials
39
As Lead Sponsor
36
As Collaborator
3
Total Enrollment
2,311
NCT00517569
Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
Phase: Phase 1
Role: Lead Sponsor
Start: Aug 31, 2006
Completion: Dec 31, 2009
NCT00513968
Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine
Start: Jul 31, 2007
Completion: Dec 31, 2010
NCT01641536
Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients
Start: Nov 30, 2011
Completion: Apr 30, 2013
NCT01634503
Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3
Start: Nov 30, 2012
Completion: Feb 28, 2014
NCT01813487
Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E
Phase: N/A
Start: Feb 28, 2013
Completion: Jul 31, 2013
NCT01951027
Phase I Study GX-G3 in Healthy Subjects
Start: Sep 30, 2013
Completion: Dec 31, 2014
NCT02100085
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
Start: Feb 28, 2014
Completion: Jan 31, 2018
NCT02079324
Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer
Start: Mar 31, 2014
Completion: Sep 30, 2016
NCT02044653
Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
Phase: Phase 2
Start: Apr 15, 2014
Completion: Apr 20, 2017
NCT02139267
Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia
Start: Jul 31, 2014
Completion: Mar 31, 2016
NCT02291991
Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects
Start: Nov 30, 2014
Completion: Jan 31, 2015
NCT02946606
A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9
Start: Jan 31, 2015
Completion: Dec 30, 2016
NCT02411019
Start: Mar 31, 2015
Completion: Nov 30, 2018
NCT02596243
Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)
Start: Aug 31, 2015
Completion: Aug 31, 2018
NCT03309891
Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency
Start: Jan 18, 2016
Completion: May 15, 2019
NCT02860715
Clinical Trial of GX-I7 in Healthy Volunteers
Start: Jul 11, 2016
Completion: Jun 2, 2018
NCT03144934
Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers
Start: Feb 16, 2017
Completion: Mar 22, 2018
NCT03206138
Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
Role: Collaborator
Start: May 30, 2017
Completion: Oct 31, 2018
NCT03651466
Safety and Tolerability of GX-G6 in Healthy Male Subjects
Start: Aug 31, 2017
Completion: Jun 28, 2018
NCT03276988
Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients
Phase: Phase 1/2
Start: Sep 7, 2017
Completion: Jan 20, 2020
NCT03478995
Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
Start: Mar 5, 2018
Completion: Mar 16, 2020
NCT03444376
The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer
Start: Jun 19, 2018
Completion: Dec 21, 2023
NCT03619239
Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma
Start: Jun 20, 2018
Completion: Sep 25, 2020
NCT03733587
GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
Start: Oct 17, 2018
Completion: May 13, 2020
NCT03752723
Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)
Start: Mar 27, 2019
Completion: May 11, 2023
NCT03962010
A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus
Start: Jun 1, 2019
Completion: Jul 1, 2022
NCT04065087
Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma
Start: Aug 22, 2019
Completion: Aug 27, 2022
NCT04445389
Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults
Start: Jun 17, 2020
Completion: Dec 17, 2020
NCT04298749
Safety and Tolerability of GX-P1 in Healthy Male Volunteers
Start: Aug 11, 2020
Completion: Jun 7, 2021
NCT04810637
A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19
Start: Nov 1, 2020
Completion: Sep 30, 2021
NCT04715997
Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults
Start: Dec 30, 2020
Completion: Apr 19, 2022
NCT04915989
Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals
Start: Feb 16, 2021
Completion: Apr 1, 2022
NCT04730427
Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19
Start: Mar 24, 2021
Completion: Jul 7, 2022
NCT05067946
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
Phase: Phase 2/3
Start: Oct 31, 2021
Completion: Oct 31, 2023
NCT05191784
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
Start: Jan 26, 2022
Completion: Dec 31, 2024
NCT05286060
Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer
Start: Mar 1, 2022
Completion: Dec 31, 2025
NCT06466785
A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Phase: Phase 3
Start: Jan 25, 2024
Completion: Sep 30, 2027
NCT06490939
Clinical Trial of Efepoetin Alfa in Healthy Subjects
Start: Oct 29, 2024
Completion: Mar 25, 2025
Loading map...